Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sention licenses compounds from Merck

Executive Summary

Sention Inc. (develops treatments for cognitive impairment and CNS disorders) has exclusively licensed from Merck & Co. Inc. a group of compounds called metabotropic glutamate receptor (mGluR) antagonists to use in the development of potential therapeutics for Fragile X mental retardation.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies